Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years.

Objectives: Initial recommendations on anti-TNF treatment for Behçet's disease (BD) included an intravenous infliximab infusion for acute posterior uveitis to achieve a fast-onset response. We aimed to examine the long-term outcome of our patients with acute sight-threatening BD who received successful short-term treatment with infliximab.

Methods: We performed a retrospective longitudinal outcome study including consecutive patients who responded to one infliximab infusion (5mg/kg) for BD-associated acute posterior uveitis or panuveitis, followed, or not, by one or two additional infusions.

Three-Year Results of Fluorescein Angiography-Guided Standard Photodynamic Therapy with Multiple Spots for Central Serous Chorioretinopathy.

Purpose: To report the long-term results of fluorescein angiography (FA)-guided standard photodynamic therapy (PDT) for central serous chorioretinopathy (CSCR) and its adverse effects.

Design: Prospective, noncomparative, interventional study.

Participants: Consecutive patients (N = 63 eyes) with acute (39 eyes) or chronic (24 eyes) CSCR.

Depression in Choroidal Melanoma Patients Treated with Proton Beam Radiotherapy.

Aim: To determine depression in patients with choroidal melanoma (CM) treated with proton beam radiotherapy.

Patients And Methods: This was a cross-sectional study including 50 patients with CM (50% males, mean age=49.88±6.

Anti-platelet effects of vitamin supplements in age-related macular degeneration: an in vitro study.

Objective: The purpose of this experimental study was to investigate the role of vitamin supplements (Ocuvite, Vitalux Omega, and Nutrof Total) as possible inhibitors of the onset of age-related macular degeneration (AMD).

Materials And Methods: The anti-aggregating effect of each vitamin was determined against four accumulative factors namely, platelet activating factor (PAF), adenosine diphosphate (ADP), thrombin receptor-activating peptide (TRAP), and arachidonic acid (AA) in the platelet rich plasma (PRP) of healthy volunteers.

Results: Ocuvite, Vitalux Omega, and Nutrof Total were more potent inhibitors against PAF and ADP compared to TRAP and AA.

Multimodal imaging of hypertensive chorioretinopathy by swept-source optical coherence tomography and optical coherence tomography angiography: Case report.

Rationale: To investigate malignant hypertension ocular lesions with swept source optical coherence tomography (SS-OCT) and optical coherence tomography angiography (OCT-A).

Patient Concerns: Visual loss due to malignant hypertension.

Diagnoses: Hypertensive chorioretinopathy.

The Impact of Chronic Tobacco Smoking on Retinal and Choroidal Thickness in Greek Population.

Aim. To investigate the effect of more than 25-year cigarette smoking on choroidal and retinal thickness, using spectral domain optical coherence tomography (SD-OCT). Methods.

Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity in retinitis pigmentosa.

Introduction: Our purpose was to study the correlation between the macular morphology and function in eyes with retinitis pigmentosa (RP).

Methods: Sixty-six eyes from 33 patients with RP and with different visual acuity (VA) were studied using optical coherence tomography (OCT) and multifocal electroretinogram (mfERG). Correlation analysis was performed between VA, macular thickness, mfERG amplitude, and latency.

Intravitreal ranibizumab treatment of macular choroidal neovascularization secondary to angioid streaks: one-year results of a prospective study.

Purpose: The purpose of this study was to evaluate the efficacy of intravitreal ranibizumab in eyes with macular choroidal neovascularization secondary to angioid streaks.

Methods: A prospective interventional case series was conducted on eyes with macular choroidal neovascularization, secondary to angioid streaks, treated by repeated injections of intravitreal ranibizumab (0.5 mg) and completing a follow-up time of 1 year.